drugset / Trial / NCT06757907

Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis

NCT06757907

Completed 20 enrolled Al-Azhar University
RandomizedParallel-groupOpen-labelTreatment

Summary

Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition

Timeline

Start
2024-10-01
Primary completion
2024-12-20
Completion
2024-12-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acyclovir Small molecule 400 mg
Comparator Ganciclovir Small molecule 0.15 % Topical